tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ross Osborn, 132 are a BUY (92.31%), 11 are a HOLD (7.69%).
Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 33.94% that have a potential upside of 44.01% achieved within 110 days.
Ross Osborn’s has documented 275 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PRE, Prenetics Global Ltd at 11-Nov-2025.
Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 10-May-2023
$1.5
$-0.02 (-1.32%)
$2
4 days ago
(06-Mar-2026)
7/8 (87.5%)
$-0.02 (-1.32%)
12
Hold Since 07-Jan-2022
$2
$0.48 (31.58%)
$1.5
3 months 27 days ago
(11-Nov-2025)
11/11 (100%)
$0.14 (7.53%)
150
Buy Since 13-Dec-2023
$2
$0.48 (31.58%)
$1.8
4 months ago
(10-Nov-2025)
3/4 (75%)
$0.24 (13.64%)
150
Buy Since 13-Oct-2020
$3
4 months 23 days ago
(15-Oct-2025)
5/13 (38.46%)
$1.62 (117.39%)
123
Buy Since 03-Jun-2024
$3
$1.48 (97.37%)
10 months 1 days ago
(09-May-2025)
1/2 (50%)
$1.88 (167.86%)
40
Which stock is Ross Osborn is most bullish on?
Which stock is Ross Osborn is most reserved on?
What Year was the first public recommendation made by Ross Osborn?
